XTX Topco’s Eupraxia Pharmaceuticals EPRX Stock Holding History

XTX Topco’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,180	Closed	-$122K	–	4496
2025 Q4	$122K	Buy	+16,180	New	+$99.7K	﹤0.01%	2582

Other funds holding EPRX

BGC

Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

XTX Topco's EPRX Position: Q1 2026 in Review

XTX Topco sold out of Eupraxia Pharmaceuticals (EPRX) in Q1 2026, closing a stake of 16,180 shares — an estimated $122K sold.

XTX Topco first reported a position in EPRX in Q4 2025 and held it in 1 quarter. The position peaked at $122K in Q4 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

XTX Topco reported no remaining Eupraxia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
XTX Topco sold 16,180 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $122K.
XTX Topco first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and held it in 1 quarter.
XTX Topco's Eupraxia Pharmaceuticals position peaked at $122K in Q4 2025.
54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.